Margaret Delday1,2, Imke Mulder1, Elizabeth T Logan1,2, George Grant1,2. 1. 4D Pharma Research Ltd, Life Science Innovation Building, Aberdeen, UK. 2. Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen UK.
Abstract
Background: Alterations in the gut microbiota are strongly associated with the development of inflammatory bowel disease (IBD), particularly with Crohn's disease, which is characterized by reduced abundance of commensal anaerobic bacteria including members of the Bacteroides genus. Our aim was to investigate the protective effects of Bacteroides thetaiotaomicron, an abundant member of this genus, in different rodent models of IBD. Methods: We assessed the effect of B. thetaiotaomicron administration on primary readouts of colitis (weight loss, histopathology, and immune parameters) in dextran sodium sulphate (DSS) and interleukin-10 knockout (IL10KO) models of IBD. Efficacy of a freeze-dried bacterial formulation and a purified recombinant protein of B. thetaiotaomicron was also investigated. Results: B. thetaiotaomicron showed protective effects in both DSS and IL10KO rodent models, as demonstrated by significant amelioration of weight loss, colon shortening, histopathological damage and immune activation. This efficacy was not exclusive to actively growing bacterial preparations but was retained by freeze-dried cells of B. thetaiotaomicron. A pirin-like protein (PLP) of B. thetaiotaomicron, identified by microarray analysis during coculture of the bacterial strain with Caco-2 cells, reduced pro-inflammatory NF-κB signalling in these intestinal epithelial cells. Recombinant PLP partially recapitulated the effect of the whole strain in a rat DSS model. Conclusions: B. thetaiotaomicron displays strong efficacy in preclinical models of IBD and protects against weight loss, histopathological changes in the colon and inflammatory markers. These data indicate that the live strain or its products may be a novel alternative to current treatment options for Crohn's disease.
Background: Alterations in the gut microbiota are strongly associated with the development of inflammatory bowel disease (IBD), particularly with Crohn's disease, which is characterized by reduced abundance of commensal anaerobic bacteria including members of the Bacteroides genus. Our aim was to investigate the protective effects of Bacteroides thetaiotaomicron, an abundant member of this genus, in different rodent models of IBD. Methods: We assessed the effect of B. thetaiotaomicron administration on primary readouts of colitis (weight loss, histopathology, and immune parameters) in dextran sodium sulphate (DSS) and interleukin-10 knockout (IL10KO) models of IBD. Efficacy of a freeze-dried bacterial formulation and a purified recombinant protein of B. thetaiotaomicron was also investigated. Results:B. thetaiotaomicron showed protective effects in both DSS and IL10KO rodent models, as demonstrated by significant amelioration of weight loss, colon shortening, histopathological damage and immune activation. This efficacy was not exclusive to actively growing bacterial preparations but was retained by freeze-dried cells of B. thetaiotaomicron. A pirin-like protein (PLP) of B. thetaiotaomicron, identified by microarray analysis during coculture of the bacterial strain with Caco-2 cells, reduced pro-inflammatory NF-κB signalling in these intestinal epithelial cells. Recombinant PLP partially recapitulated the effect of the whole strain in a ratDSS model. Conclusions: B. thetaiotaomicron displays strong efficacy in preclinical models of IBD and protects against weight loss, histopathological changes in the colon and inflammatory markers. These data indicate that the live strain or its products may be a novel alternative to current treatment options for Crohn's disease.
Authors: Scott Horowitz; David G Binion; Victoria M Nelson; Yasmin Kanaa; Pooria Javadi; Zelmira Lazarova; Christopher Andrekopoulos; Balaraman Kalyanaraman; Mary F Otterson; Parvaneh Rafiee Journal: Am J Physiol Gastrointest Liver Physiol Date: 2007-01-11 Impact factor: 4.052
Authors: D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808
Authors: Thomas D Walters; Mi-Ok Kim; Lee A Denson; Anne M Griffiths; Marla Dubinsky; James Markowitz; Robert Baldassano; Wallace Crandall; Joel Rosh; Marian Pfefferkorn; Anthony Otley; Melvin B Heyman; Neal LeLeiko; Susan Baker; Stephen L Guthery; Jonathan Evans; David Ziring; Richard Kellermayer; Michael Stephens; David Mack; Maria Oliva-Hemker; Ashish S Patel; Barbara Kirschner; Dedrick Moulton; Stanley Cohen; Sandra Kim; Chunyan Liu; Jonah Essers; Subra Kugathasan; Jeffrey S Hyams Journal: Gastroenterology Date: 2013-10-23 Impact factor: 22.682
Authors: Faith D Ihekweazu; Melinda A Engevik; Wenly Ruan; Zhongcheng Shi; Robert Fultz; Kristen A Engevik; Alexandra L Chang-Graham; Jasmin Freeborn; Evelyn S Park; Susan Venable; Thomas D Horvath; Sigmund J Haidacher; Anthony M Haag; Annie Goodwin; Deborah A Schady; Joseph M Hyser; Jennifer K Spinler; Yuying Liu; James Versalovic Journal: Am J Pathol Date: 2021-01-28 Impact factor: 4.307